Charles Mango, MD
Ophthalmology · Syracuse, NYNPI 1285637611
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,850 of the $2,883 with a category attached, or 64.2%. Eyepoint US, Inc. accounts for 71.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $2,023 and has fallen 97.1% since, to $58 in 2025.
Across 30 payments — averaging $96.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$2K
- Dutch Ophthalmic, USA$238
- Apellis Pharmaceuticals, Inc.$218
- Alimera Sciences, Inc.$116
- Carl Zeiss Meditec, Inc.$58
- Regeneron Healthcare Solutions, Inc.$42
- plus $141 from 5 others
What the payments were for
- Consulting fees$1,85064%
- Food & beverage$1,03336%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 7 | $2,071 |
| Dutch Ophthalmic, USA | 2 | $238 |
| Apellis Pharmaceuticals, Inc. | 3 | $218 |
| Alimera Sciences, Inc. | 9 | $116 |
| Carl Zeiss Meditec, Inc. | 1 | $58 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Genentech USA, Inc. | 2 | $40 |
| AbbVie | 1 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Coherus Oncology, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,883 in reported general payments places this provider in the 65th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ofloxacin | 51 | $458 |
| Levothyroxine Sodium | 13 | $96 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Syracuse
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.